South Delhi Pharma, New Delhi, India
Trastuzumab Intravenous Infusion
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
Facts of Trastuzumab
Initial U.S. Approval: 1998
Strength:
1. For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution
2. For Injection: 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “trastuzumab” to all locations in the world and in India after fulfilling the legal requirement (if applicable). trastuzumab is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
What Trastuzumab is ?
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication.
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines. A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.
What are the Alternate Brands of Trastuzumab?
- Trasmab™ By Aureate Healthcare.
- Herceptin By Genentech
- Hertraz By Mylan
- Eleftha By Intas
- CanMab By Biocon
- Vivitra By Zydus
- Herclon By Roche
- Trasturel By Reliance
- Biceltis By Emucure
